BUZZ - Caribou shares fall after discontinuing cell therapy program and launching strategic review
路透社2026/10/06 21:03On October 6th, shares of biotech company Caribou Biosciences (CRBU.O) fell by 36.1% in after-hours trading to $0.73. The company announced it is exploring potential sale, merger, or other options to unlock shareholder value. Caribou plans to discontinue the development of its experimental cell therapy vispa-cel for a certain blood cancer, as well as CB-011 for treating the bone marrow cancer—multiple myeloma. The company stated that vispa-cel is ready for clinical trials, and it has reached an agreement with the FDA on the design for late-stage clinical trials. However, the difficult financing environment for allogeneic CAR-T therapies has made it challenging to raise the necessary funds to advance these projects. Caribou also intends to lay off employees and cut costs; according to its report, as of June 30, 2026, the company held $113.8 million in cash, cash equivalents, and marketable securities. As of the previous trading day’s close, the stock had fallen about 29% year-to-date. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several languages. As automated translations may contain errors or lack context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for reader convenience. Reuters assumes no liability for any harm or loss from use of the automated translation feature.)
October 6 - ** Biotechnology company Caribou Biosciences CRBU.O shares fell 36.1% in after-hours trading, to $0.73
** The company announced it is exploring potential sale, merger, or other options to unlock shareholder value
** The company plans to cease development of the experimental cell therapy vispa-cel for a type of blood cancer, as well as CB-011 for treating multiple myeloma, a bone marrow cancer
** The company stated that vispa-cel is ready for clinical trials and that it has reached agreement with the US Food and Drug Administration (FDA) on the design for advanced clinical trials
** The company noted that the harsh funding environment for allogeneic CAR-T therapies makes it difficult to raise the funds needed to advance these projects
** Caribou plans to cut staff and reduce costs; according to the company report, as of June 30, 2026, it held $113.8 million in cash, cash equivalents, and marketable securities
** As of the close of the last trading session, the stock had fallen about 29% year to date
(To assist non-native English speakers, Reuters has automatically translated this report into several other languages. As automated translation may be inaccurate or may not fully capture the intended context, Reuters does not guarantee the accuracy of this automated translation, which is provided solely for the convenience of readers. Reuters accepts no liability for any damages or losses arising from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
McDonald's (MCD.US) sued over AI pricing tool, accused of facilitating algorithmic collusion among U.S. franchisees
McDonald's (MCD.US) is facing a federal lawsuit. The complaint alleges that its AI-enhanced pricing tool violates antitrust laws by sharing non-public data with franchisees who may compete in the same market.
Samsung Electronics delivers its strongest quarterly report ever; can HBM4e restart AI memory trading?
Samsung Electronics is about to face a critical test. The company will release its preliminary results on Thursday, and it is expected to record its largest-ever quarterly operating profit. However, the real test is not the scale of profits, but whether it can convince investors that the demand for memory chips is sustainable and that high product prices can be secured through long-term contracts.
BUZZ - Australian uranium mining stocks surge after Google reaches power deal with Constellation Energy
October 7 - Shares of Australian uranium mining companies surged after Google (GOOGL.O) signed a power agreement with Constellation Energy (CEG.O), the largest nuclear power plant operator in the United States (link). Google (GOOGL) and Constellation Energy (CEG) have entered into a multi-year deal under which Google will purchase 3,590 megawatts of electricity from Constellation; according to both parties, the additional nuclear-generated electricity accounts for roughly a quarter of total supplied power. Uranium is primarily used as fuel for nuclear power plants to generate low-carbon electricity. Boss Energy (BOE.AX) shares rose 9%, reaching their highest level since September 29, while Paladin Energy (PDN.AX) shares climbed over 6%. Deep Yellow (DYL.AX) shares rose nearly 10%, marking their largest intraday gain since September 3. Within the broadly flat ASX200 benchmark index (.AXJO), DYL and PDN ranked among the top gainers. (For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Since automated translations may contain errors or lack the necessary context, Reuters does not guarantee their accuracy and provides them solely for reader convenience. Reuters accepts no responsibility for any damage or loss arising from the use of the automated translation function.)
12.41 million dollars in fee revenue, Pump.fun transferred to an exchange 9 hours ago
